SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 104 300 KRW -0.57% Market Closed
Market Cap: 8.2T KRW
Section:
Profitability Summary
Profitability Summary
Past Growth
Margins
Return on Capital
Free Cash Flow
See Also

Profitability Summary

SK Biopharmaceuticals Co Ltd's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less
0
Revenue
+0%
3Y
+31%
5Y
+342%
10Y
-
0
Operating Income
+0%
3Y
+1%
5Y
-
10Y
-
0
Net Income
+0%
3Y
+271%
5Y
-
10Y
-

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
SK Biopharmaceuticals Co Ltd

Revenue
547.6B KRW
Cost of Revenue
-43.1B KRW
Gross Profit
504.5B KRW
Operating Expenses
-408.2B KRW
Operating Income
96.3B KRW
Other Expenses
144.4B KRW
Net Income
240.7B KRW

Margins Comparison
SK Biopharmaceuticals Co Ltd Competitors

Country Company Market Cap Gross
Margin 		Operating
Margin 		Net
Margin
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
8.2T KRW
92%
18%
44%
US
Eli Lilly and Co
NYSE:LLY
785.9B USD
81%
38%
24%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
374B USD
68%
26%
24%
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
85%
48%
35%
CH
Roche Holding AG
SIX:ROG
206.3B CHF
74%
33%
14%
CH
Novartis AG
SIX:NOVN
186.3B CHF
75%
32%
23%
UK
AstraZeneca PLC
LSE:AZN
160.9B GBP
82%
23%
13%
US
Merck & Co Inc
NYSE:MRK
199.4B USD
81%
36%
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
68%
11%
-126%
FR
Sanofi SA
PAR:SAN
116.5B EUR
70%
21%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
SK Biopharmaceuticals Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
8.2T KRW
58%
27%
17%
51%
US
Eli Lilly and Co
NYSE:LLY
785.9B USD
85%
15%
39%
22%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
374B USD
31%
13%
19%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
81%
26%
71%
33%
CH
Roche Holding AG
SIX:ROG
206.3B CHF
27%
9%
29%
20%
CH
Novartis AG
SIX:NOVN
186.3B CHF
27%
12%
23%
17%
UK
AstraZeneca PLC
LSE:AZN
160.9B GBP
18%
7%
17%
14%
US
Merck & Co Inc
NYSE:MRK
199.4B USD
42%
15%
28%
21%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
70%
-51%
5%
6%
FR
Sanofi SA
PAR:SAN
116.5B EUR
8%
4%
9%
7%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 248,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.